---
document_datetime: 2025-12-02 06:43:28
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/imatinib-actavis.html
document_name: imatinib-actavis.html
version: success
processing_time: 0.1084106
conversion_datetime: 2025-12-25 01:22:06.796501
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Imatinib Actavis

[RSS](/en/individual-human-medicine.xml/66757)

##### Withdrawn

This medicine's authorisation has been withdrawn

imatinib Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 16 May 2022, the European Commission withdrew the marketing authorisation for Imatinib Actavis (imatinib) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Actavis Group PTC ehf., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Imatinib Actavis was granted marketing authorisation in the EU on 17 April 2013 for treatment of:

- paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment;
- paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;
- adult patients with Ph+ CML in blast crisis;
- adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy;
- adult patients with relapsed or refractory Ph+ ALL as monotherapy;
- adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with plateletderived growth factor receptor (PDGFR) gene re-arrangements;
- adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRα rearrangement;
- adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.

The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2017.

Imatinib Actavis is a generic medicine of Glivec. There are other generic medicinal products of Glivec authorised and marketed in the EU.

The European Public Assessment Report (EPAR) for Imatinib Actavis is updated to indicate that the marketing authorisation is no longer valid.

Imatinib Actavis : EPAR - Medicine overview

Reference Number: EMA/30081/2019

English (EN) (646.13 KB - PDF)

**First published:** 06/05/2013

**Last updated:** 05/07/2022

[View](/en/documents/overview/imatinib-actavis-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-827)

български (BG) (736.51 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/bg/documents/overview/imatinib-actavis-epar-medicine-overview_bg.pdf)

español (ES) (650.53 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/es/documents/overview/imatinib-actavis-epar-medicine-overview_es.pdf)

čeština (CS) (713.38 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/cs/documents/overview/imatinib-actavis-epar-medicine-overview_cs.pdf)

dansk (DA) (642.88 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/da/documents/overview/imatinib-actavis-epar-medicine-overview_da.pdf)

Deutsch (DE) (651.32 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/de/documents/overview/imatinib-actavis-epar-medicine-overview_de.pdf)

eesti keel (ET) (651.05 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/et/documents/overview/imatinib-actavis-epar-medicine-overview_et.pdf)

ελληνικά (EL) (735.68 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/el/documents/overview/imatinib-actavis-epar-medicine-overview_el.pdf)

français (FR) (651.12 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/fr/documents/overview/imatinib-actavis-epar-medicine-overview_fr.pdf)

hrvatski (HR) (661.19 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/hr/documents/overview/imatinib-actavis-epar-medicine-overview_hr.pdf)

italiano (IT) (642.56 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/it/documents/overview/imatinib-actavis-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (717.83 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/lv/documents/overview/imatinib-actavis-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (664.16 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/lt/documents/overview/imatinib-actavis-epar-medicine-overview_lt.pdf)

magyar (HU) (708.81 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/hu/documents/overview/imatinib-actavis-epar-medicine-overview_hu.pdf)

Malti (MT) (713.36 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/mt/documents/overview/imatinib-actavis-epar-medicine-overview_mt.pdf)

Nederlands (NL) (647.06 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/nl/documents/overview/imatinib-actavis-epar-medicine-overview_nl.pdf)

polski (PL) (712.5 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/pl/documents/overview/imatinib-actavis-epar-medicine-overview_pl.pdf)

português (PT) (643.74 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/pt/documents/overview/imatinib-actavis-epar-medicine-overview_pt.pdf)

română (RO) (662.21 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/ro/documents/overview/imatinib-actavis-epar-medicine-overview_ro.pdf)

slovenčina (SK) (713 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/sk/documents/overview/imatinib-actavis-epar-medicine-overview_sk.pdf)

slovenščina (SL) (705.41 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/sl/documents/overview/imatinib-actavis-epar-medicine-overview_sl.pdf)

Suomi (FI) (649.29 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/fi/documents/overview/imatinib-actavis-epar-medicine-overview_fi.pdf)

svenska (SV) (646.89 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/sv/documents/overview/imatinib-actavis-epar-medicine-overview_sv.pdf)

## Product information

Imatinib Actavis : EPAR - Product Information

English (EN) (1.42 MB - PDF)

**First published:** 06/05/2013

**Last updated:** 05/07/2022

[View](/en/documents/product-information/imatinib-actavis-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-527)

български (BG) (4.74 MB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/bg/documents/product-information/imatinib-actavis-epar-product-information_bg.pdf)

español (ES) (1.37 MB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/es/documents/product-information/imatinib-actavis-epar-product-information_es.pdf)

čeština (CS) (3.37 MB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/cs/documents/product-information/imatinib-actavis-epar-product-information_cs.pdf)

dansk (DA) (1.42 MB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/da/documents/product-information/imatinib-actavis-epar-product-information_da.pdf)

Deutsch (DE) (1.49 MB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/de/documents/product-information/imatinib-actavis-epar-product-information_de.pdf)

eesti keel (ET) (1.37 MB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/et/documents/product-information/imatinib-actavis-epar-product-information_et.pdf)

ελληνικά (EL) (4.55 MB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/el/documents/product-information/imatinib-actavis-epar-product-information_el.pdf)

français (FR) (1.46 MB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/fr/documents/product-information/imatinib-actavis-epar-product-information_fr.pdf)

hrvatski (HR) (1.52 MB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/hr/documents/product-information/imatinib-actavis-epar-product-information_hr.pdf)

íslenska (IS) (1.36 MB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/is/documents/product-information/imatinib-actavis-epar-product-information_is.pdf)

italiano (IT) (1.45 MB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/it/documents/product-information/imatinib-actavis-epar-product-information_it.pdf)

latviešu valoda (LV) (3.49 MB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/lv/documents/product-information/imatinib-actavis-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.59 MB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/lt/documents/product-information/imatinib-actavis-epar-product-information_lt.pdf)

magyar (HU) (3.47 MB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/hu/documents/product-information/imatinib-actavis-epar-product-information_hu.pdf)

Malti (MT) (3.47 MB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/mt/documents/product-information/imatinib-actavis-epar-product-information_mt.pdf)

Nederlands (NL) (1.43 MB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/nl/documents/product-information/imatinib-actavis-epar-product-information_nl.pdf)

norsk (NO) (1.38 MB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/no/documents/product-information/imatinib-actavis-epar-product-information_no.pdf)

polski (PL) (3.64 MB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/pl/documents/product-information/imatinib-actavis-epar-product-information_pl.pdf)

português (PT) (1.45 MB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/pt/documents/product-information/imatinib-actavis-epar-product-information_pt.pdf)

română (RO) (1.61 MB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/ro/documents/product-information/imatinib-actavis-epar-product-information_ro.pdf)

slovenčina (SK) (3.59 MB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/sk/documents/product-information/imatinib-actavis-epar-product-information_sk.pdf)

slovenščina (SL) (3.32 MB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/sl/documents/product-information/imatinib-actavis-epar-product-information_sl.pdf)

Suomi (FI) (1.48 MB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/fi/documents/product-information/imatinib-actavis-epar-product-information_fi.pdf)

svenska (SV) (1.36 MB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/sv/documents/product-information/imatinib-actavis-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IA/0020 16/12/2021

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Imatinib Actavis : EPAR - All Authorised presentations

English (EN) (593.89 KB - PDF)

**First published:** 06/05/2013

**Last updated:** 05/07/2022

[View](/en/documents/all-authorised-presentations/imatinib-actavis-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-557)

български (BG) (668.32 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/bg/documents/all-authorised-presentations/imatinib-actavis-epar-all-authorised-presentations_bg.pdf)

español (ES) (594.48 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/es/documents/all-authorised-presentations/imatinib-actavis-epar-all-authorised-presentations_es.pdf)

čeština (CS) (611.97 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/cs/documents/all-authorised-presentations/imatinib-actavis-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (594.79 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/da/documents/all-authorised-presentations/imatinib-actavis-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (595.37 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/de/documents/all-authorised-presentations/imatinib-actavis-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (594.23 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/et/documents/all-authorised-presentations/imatinib-actavis-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (643.06 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/el/documents/all-authorised-presentations/imatinib-actavis-epar-all-authorised-presentations_el.pdf)

français (FR) (595.13 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/fr/documents/all-authorised-presentations/imatinib-actavis-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (616.26 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/hr/documents/all-authorised-presentations/imatinib-actavis-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (594.5 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/is/documents/all-authorised-presentations/imatinib-actavis-epar-all-authorised-presentations_is.pdf)

italiano (IT) (596.97 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/it/documents/all-authorised-presentations/imatinib-actavis-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (632.86 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/lv/documents/all-authorised-presentations/imatinib-actavis-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (619.91 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/lt/documents/all-authorised-presentations/imatinib-actavis-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (650.68 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/hu/documents/all-authorised-presentations/imatinib-actavis-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (638.58 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/mt/documents/all-authorised-presentations/imatinib-actavis-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (593.76 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/nl/documents/all-authorised-presentations/imatinib-actavis-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (594.81 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/no/documents/all-authorised-presentations/imatinib-actavis-epar-all-authorised-presentations_no.pdf)

polski (PL) (632.11 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/pl/documents/all-authorised-presentations/imatinib-actavis-epar-all-authorised-presentations_pl.pdf)

português (PT) (595.03 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/pt/documents/all-authorised-presentations/imatinib-actavis-epar-all-authorised-presentations_pt.pdf)

română (RO) (615.27 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/ro/documents/all-authorised-presentations/imatinib-actavis-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (633.12 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/sk/documents/all-authorised-presentations/imatinib-actavis-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (631.3 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/sl/documents/all-authorised-presentations/imatinib-actavis-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (596.64 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/fi/documents/all-authorised-presentations/imatinib-actavis-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (594.08 KB - PDF)

**First published:**

06/05/2013

**Last updated:**

05/07/2022

[View](/sv/documents/all-authorised-presentations/imatinib-actavis-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Imatinib Actavis Active substance imatinib International non-proprietary name (INN) or common name imatinib Therapeutic area (MeSH)

- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Myelodysplastic-Myeloproliferative Diseases
- Hypereosinophilic Syndrome
- Dermatofibrosarcoma

Anatomical therapeutic chemical (ATC) code L01EA01

### Pharmacotherapeutic group

- Protein kinase inhibitors
- Antineoplastic agents

### Therapeutic indication

Imatinib Actavis is indicated for the treatment of:

- paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment;
- paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;
- adult patients with Ph+ CML in blast crisis;
- adult patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy;
- adult patients with relapsed or refractory Ph+ ALL as monotherapy;
- adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements;
- adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFR rearrangement;
- the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.

The effect of imatinib on the outcome of bone marrow transplantation has not been determined.

Imatinib Actavis is indicated for:

- In adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS/MPD, on haematological response rates in HES/CEL and on objective response rates in adult patients with unresectable and/or metastatic DFSP. The experience with imatinib in patients with MDS/MPD associated with PDGFR gene re-arrangements is very limited. There are no controlled trials demonstrating a clinical benefit or increased survival for these diseases.

## Authorisation details

EMA product number EMEA/H/C/002594

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Actavis Group PTC ehf

Dalshraun 1

Opinion adopted 21/02/2013 Marketing authorisation issued 17/04/2013 Revision 13

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Imatinib Actavis : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (732.49 KB - PDF)

**First published:** 24/06/2013

**Last updated:** 05/07/2022

[View](/en/documents/procedural-steps-after/imatinib-actavis-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Imatinib Actavis-H-C-2594-X-0003 : EPAR - Assessment Report - Extension

Adopted

Reference Number: EMA/284461/2014

English (EN) (1.05 MB - PDF)

**First published:** 10/07/2014

**Last updated:** 10/07/2014

[View](/en/documents/variation-report/imatinib-actavis-h-c-2594-x-0003-epar-assessment-report-extension_en.pdf)

## Initial marketing authorisation documents

Imatinib Actavis : EPAR - Public assessment report

Adopted

English (EN) (1.04 MB - PDF)

**First published:** 06/05/2013

**Last updated:** 05/07/2022

[View](/en/documents/assessment-report/imatinib-actavis-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Imatinib Actavis

Adopted

Reference Number: EMA/CHMP/82403/2013

English (EN) (633.84 KB - PDF)

**First published:** 22/02/2013

**Last updated:** 05/07/2022

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-imatinib-actavis_en.pdf)

**This page was last updated on** 05/07/2022

## Share this page

[Back to top](#main-content)